ARCA biopharma Release: Gencaro Effect on Reducing Ventricular Arrhythmias Paper Published in Circulation: Arrhythmia and Electrophysiology
1/3/2013 9:42:52 AM
BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper "Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias with Bucindolol in Patients with Chronic Heart Failure” was published in the journal Circulation: Arrhythmia and Electrophysiology [http://circep.ahajournals.org/content/early/recent], a publication of the American Heart Association. The lead author on the paper is cardiologist-electrophysiologist Ryan G. Aleong of the University of Colorado Anschutz Medical Campus.
comments powered by